Display options
Cite
Francescon S, Fornasier G, Baldo P. Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations. Oncol Ther. 2016;4(2):173-182doi: 10.1007/s40487-016-0028-9.
Francescon, S., Fornasier, G., & Baldo, P. (2016). Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations. Oncology and therapy, 4(2), 173-182. https://doi.org/10.1007/s40487-016-0028-9
Francescon, Sara, et al. "Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations." Oncology and therapy vol. 4,2 (2016): 173-182. doi: https://doi.org/10.1007/s40487-016-0028-9
Francescon S, Fornasier G, Baldo P. Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations. Oncol Ther. 2016;4(2):173-182. doi: 10.1007/s40487-016-0028-9. Epub 2016 Aug 11. PMID: 28261647; PMCID: PMC5315076.
Copy Download .nbib Format: NLM
Share it on

Oncol Ther. 2016;4(2):173-182. doi: 10.1007/s40487-016-0028-9. Epub 2016 Aug 11.

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations.

Oncology and therapy

Sara Francescon, Giulia Fornasier, Paolo Baldo

Affiliations

  1. Pharmacy Division, CRO National Cancer Institute, Aviano, Italy.

PMID: 28261647 PMCID: PMC5315076 DOI: 10.1007/s40487-016-0028-9

Abstract

The introduction in clinical practice of pharmaceutical products known as biosimilars, as part of a more complex series of progress in the field of biological drugs, represents an excellent therapeutic resource. A biosimilar drug is a biological/biotechnological drug that is highly similar to an approved reference biologic product. Given their complexity, biosimilars require attention and a continued vigilance to ensure appropriate use, especially in cancer therapy. There is the urgent need, both at Italian and European levels, of clear and more comprehensive guidelines to elucidate the open questions. Probably, the acquisition of new data, obtained from larger samples of patients than those used in the pre-approval studies and with extremely variable clinical conditions, will allow clarifying the extent to which biosimilar drugs are similar in safety and efficacy to their biologic reference drug. The aims of this article are to provide health professionals with basic, but essential information about biosimilars, and to identify current critical points and future perspectives for clinical practice, cancer care, regulatory aspects, and pharmacovigilance.

Keywords: Biosimilars; Europe; Oncology; Pharmacovigilance

References

  1. Int J Appl Basic Med Res. 2014 Jul;4(2):63-6 - PubMed
  2. Indian J Med Paediatr Oncol. 2013 Oct;34(4):292-8 - PubMed
  3. Drug Saf. 2014 Jan;37(1):9-18 - PubMed
  4. Biosimilars. 2013 Jun 14;2013(3):19-25 - PubMed
  5. Lancet Oncol. 2014 Dec;15(13):e594-605 - PubMed
  6. N Engl J Med. 2002 Feb 14;346(7):469-75 - PubMed
  7. J Crohns Colitis. 2014 Mar;8(3):258 - PubMed
  8. J Eval Clin Pract. 2014 Oct;20(5):559-69 - PubMed
  9. Ann Oncol. 2013 Sep;24 Suppl 5:v23-8 - PubMed

Publication Types